Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company demonstrates strong operational resilience and growth driven by innovation. Despite a competitive industry landscape, the company reported a revenue of 942 million yuan in 2024, a decrease of 11.48% year-on-year, but showed a recovery in Q1 2025 with a revenue of 245 million yuan, an increase of 19.65% year-on-year. The net profit for 2024 was 382 million yuan, down 3.43%, while Q1 2025 net profit rose by 24.08% to 108 million yuan. The profit forecasts for 2025-2027 have been adjusted upwards, with expected net profits of 467 million, 578 million, and 694 million yuan respectively, corresponding to EPS of 1.00, 1.24, and 1.49 yuan [3][4][5]. Financial Performance Summary - In Q1 2025, the company's core products saw significant revenue contributions: pseudorabies vaccine accounted for 25%, diarrhea vaccine 30%, and circovirus vaccine approximately 25%. Direct sales contributed over 60% of revenue, while distribution accounted for over 30%. The gross margin and net margin for Q1 2025 were 65.88% and 43.96%, respectively, with a year-on-year change of -0.76% and +1.47 percentage points. The company has effectively reduced costs, leading to improved net margins [4][5]. - The company maintained a high level of R&D investment, totaling 86 million yuan in 2024, which is 9.14% of revenue, an increase of 0.82 percentage points year-on-year. New vaccine registrations for pigs and poultry have been achieved, and the company is expanding its product line for ruminant vaccines [5][6]. Financial Forecasts - The financial forecasts indicate a recovery trajectory with projected revenues of 1.131 billion yuan in 2025, 1.358 billion yuan in 2026, and 1.567 billion yuan in 2027, reflecting year-on-year growth rates of 20.1%, 20.1%, and 15.4% respectively. The net profit is expected to grow at rates of 22.0%, 23.9%, and 20.0% for the same years [6][8]. - Key financial ratios include a gross margin of 68.0% in 2025, improving to 71.4% by 2027, and a net margin projected to reach 44.3% by 2027 [6][8]. Valuation Metrics - The current price-to-earnings (P/E) ratios are projected at 16.2 for 2025, 13.1 for 2026, and 10.9 for 2027, indicating a favorable valuation trend as earnings grow [6][8]. - The price-to-book (P/B) ratios are expected to decline from 1.7 in 2025 to 1.4 in 2027, suggesting an attractive investment opportunity as the company continues to enhance its profitability [6][8].

证券研究报告 医药生物 | 化学制药 非金融|公司点评报告 hyzqdatemark 2025 年 04 月 30 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 李强 SAC：S1350524040001 liqiang01@huayuanstock.com 市场表现： | 基本数据 | | | | 年 | 04 | 30 | 日 | 2025 | 月 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | | | | 36.21 | | 一 年 高 / 低 | 最 | 最 | 38.08/25.72 | | | | | | | | | （元） | | | | | | | | | | | | 总市值（百万元） | | | | | | 57,865.51 | | | | | | 流通市值（百万元） | | | | | | 47,285.72 | | | | | | 总股本（百万股） | | | | | | | | ...

Core Viewpoint - The company reported Q1 2025 performance with revenue of 9.898 billion yuan, a year-on-year decrease of 2.82%, and a net profit attributable to shareholders of 0.886 billion yuan, down 7.32%, exceeding market expectations mainly due to price increases in cultural paper and cost control [1] Financial Performance - Q1 2025 paper profit recovery: Average prices for double glue paper, copper plate paper, and box board paper increased by 122, 211, and 65 yuan per ton respectively compared to the previous quarter, while inventory pulp costs declined, indicating a recovery in paper profit, particularly in cultural paper [1] - Stable external pulp sales: The company's external pulp capacity remained stable at 1.44 million tons for 2023-2024, primarily serving the group with stable consumption and minimal profit fluctuations [1] - High capital expenditure: Operating cash flow for Q1 2025 was 0.124 billion yuan, down 79% year-on-year, with capital expenditure at 1.97 billion yuan as the Guangxi base is in a peak expansion phase; the debt-to-asset ratio stands at 46% [1] Development Trends - Optimistic outlook for Q2 2025 performance: As of April 23, 2025, average prices for double glue paper and copper plate paper were 5,775 and 6,071 yuan per ton, showing a slight decrease and increase respectively compared to Q1 2025; the cultural paper market is in a traditional peak season, but price increases may be limited due to rapid declines in pulp prices [2] - Expected completion of dissolving pulp relocation in May, which is anticipated to leverage regional advantages in Guangxi, further reducing costs and enhancing production and sales levels [2] Strategic Initiatives - Three major bases working in synergy: The Laos base is focused on rapid afforestation, aiming to add over 10,000 hectares annually; the Guangxi base is expected to complete projects by the end of 2025, producing 1 million tons of high-end packaging paper and 150,000 tons of household paper; the Shandong base plans to trial production of 37,000 tons of specialty paper by April 2025 [3] - Long-term cost advantages are expected to be realized through overseas land reserves, with potential for resource-based asset revaluation [3] Profit Forecast and Valuation - The company maintains its profit forecast, with current prices corresponding to P/E ratios of 12.5x and 11.7x for 2025-2026; the target price remains at 18 yuan, implying a 27% upside potential based on P/E ratios of 16x and 15x for the same period [4]

证券代码：301252 证券简称：同星科技 浙江同星科技股份有限公司 投资者关系活动记录表 编号：2025-001 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称及 | 中信证券 王涛 | | 人员姓名 | 野村资管 李行杰 | | 时间 2025 | 年 4 月 30 日上午 | | 地点 | 公司会议室 | | 上市公司接待人 | 董事会秘书：梁路芳 | | 员姓名 | 证券事务代表：潘晨曦 | | | 1、公司 2025 年的工作重点和目标是什么？在客户拓展及新业 | | | 务开发上有哪些布局？ | | | 答：公司将积极围绕 2025 年度经营方针"降本增效 全员共担共 | | | 享，高效服务 获取市场机会，苦练内功 营造竞争优势"来制定工作 | | | 目标，推动公司稳步发展。同时，公司积极在海外市场进行布局，现 | | | 已在泰国设立公司，筹建海外生产基地，进一步加快全球化步伐，为 | | 投资者关系活动 | 公司可持续发展 ...

Core Insights - The company reported a revenue of 753.11 billion yuan for Q1 2025, a year-on-year decrease of 7.3%, while net profit attributable to shareholders increased by 2.3% to 46.81 billion yuan [1] - The oil and gas business contributed to a slight increase in operating profit, which reached 65.18 billion yuan, up 0.8% year-on-year [1] Group 1: Oil and Gas Performance - The company achieved an oil and gas equivalent production of 46.7 million barrels, a year-on-year increase of 0.7%, with crude oil production at 24 million barrels, up 0.3% [2] - Natural gas production reached 13.613 billion cubic feet, a year-on-year increase of 1.2%, while the average selling price of natural gas decreased by 3.9% to 9.01 USD per thousand cubic feet [2] - The unit operating cost for oil and gas was 9.76 USD per barrel, down 6.0% year-on-year, indicating effective cost reduction [2] Group 2: Refining and Chemical Business - The company processed 33.7 million barrels of crude oil, a decrease of 4.7% year-on-year, with refined product output declining across gasoline, diesel, and kerosene [3] - The operating profit margin for refining and chemical business was 1.9%, down 0.7 percentage points year-on-year, reflecting reduced profitability [3] - The company is focusing on chemical transformation, with ethylene production remaining stable at 2.27 million tons, while synthetic resin and polymer production showed mixed results [3] Group 3: Shareholder Confidence - The controlling shareholder, China National Petroleum Corporation, plans to increase its stake in the company by investing between 2.8 billion and 5.6 billion yuan over the next 12 months, representing 0.2% to 0.4% of the company's total market value as of April 29, 2025 [4] Group 4: Investment Outlook - The company is positioned as a leading player in the domestic oil and gas sector, with rich upstream resources and a complete downstream supply chain [5] - Projected net profits for 2025 to 2027 are 143.13 billion, 154.33 billion, and 164.36 billion yuan, with corresponding EPS of 0.78, 0.84, and 0.90 yuan per share [5]

证券代码：002796 证券简称：世嘉科 技 苏州市世嘉科技股份有限公司 投资者关系活动记录表 编号：2025-001 | | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | 投资者关系活动 类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及 | | | 人员姓名 | 线上参与公司2024年度网上业绩说明会的全体投资者 | | 时间 | 2025年04月30日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 王娟女士 | | 上市公司接待人 | 独立董事 张瑞稳先生 | | 员姓名 | 董事会秘书 康云华先生 | | | 财务总监 周燕飞先生 | | | 1. 公司今年为什么又不分红？ | | | 答：您好，根据审计机构出具的2024年度审计报告，本公司合并口径可 | | | 供股东分配的利润和母公司口径可供股东分配的利润均为负数。根据《公司 | | | 章程》有关规定2024年度公司不具备现 ...

Group 1: Financial Performance - The company's net profit for 2024 was -113 million CNY, indicating a loss despite revenue growth [2] - The gross margin for the copper-clad laminate business in 2024 was 3.18%, with a net profit of -8.3 million CNY, primarily due to high initial investments for market expansion [3][4] Group 2: Business Strategy and Market Position - The company aims to improve profitability and gross margin through cost optimization, material cost control, and customer structure optimization [1] - The veterinary vaccine business is focusing on developing specialty products and implementing a "big product, big customer" strategy to enhance its market position over the next 3-5 years [2][3] Group 3: New Business Developments - The company has recently entered the copper-clad laminate and animal nutrition (feed) sectors, which are expected to have significant growth potential due to increasing demand in various industries [2][3] - The competitive advantages in the new businesses lie in production processes, management teams, and technological accumulation [2] Group 4: Future Outlook and Plans - The company plans to maintain stable operations in the feed business while actively expanding market reach and improving cost control to enhance profitability [4] - Future business development will focus on a dual main business model of "electronic information + animal health," leveraging technology to enhance industry positioning [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has experienced a slowdown in revenue growth, but cost reduction and efficiency improvements are expected to enhance profitability [3][7] - For FY2025 Q3, the company reported revenue of $1.18 billion, a year-over-year decrease of 2%, while net profit attributable to shareholders was $90 million, reflecting a year-over-year increase of 0.1% [6][8] - The company anticipates a revenue guidance for FY2025 Q4 of $1.01 to $1.04 billion, representing a year-over-year growth of 10% to 13% [8][12] Revenue Performance - The company's FY2025 Q3 revenue was $1.18 billion, with the education business (excluding Dongfang Zhenxuan) generating $1.04 billion, which is a year-over-year increase of 21.2%, exceeding previous guidance of 18% to 21% [8][12] - The gross profit for FY2025 Q3 was $650 million, with a gross margin of 55.1%, an increase of 8.5 percentage points year-over-year, primarily due to cost reduction and efficiency improvements [8][12] Profitability Metrics - Operating profit for FY2025 Q3 was $120 million, a year-over-year increase of 9.8%, with an operating margin of 10.5%, up 1.1 percentage points year-over-year [8][12] - Non-GAAP operating profit was $140 million, a year-over-year decrease of 0.2%, with a Non-GAAP operating margin of 12%, slightly above Bloomberg consensus expectations of 10.8% [8][12] Financial Position - As of the end of FY2025 Q3, the company had cash and cash equivalents of $1.42 billion, time deposits of $1.41 billion, and short-term investments of $1.85 billion [8][12] - The company has a strong brand reputation and operational experience in the education sector, which supports its profitability outlook despite challenges in traditional study abroad and new cultural tourism businesses [12] Future Projections - The company is projected to achieve revenues of $4.86 billion, $5.53 billion, and $6.27 billion for FY2025, FY2026, and FY2027, respectively, with net profits of $414 million, $514 million, and $617 million for the same periods [11][12] - The report anticipates a PE ratio of 19, 15, and 13 for FY2025, FY2026, and FY2027, respectively, indicating a favorable valuation outlook [12]

Core Viewpoint - The company, 恒星科技, is focusing on enhancing its competitive edge through technological upgrades and cost optimization in both its metal products and chemical sectors, particularly in organic silicon production [2][3][4]. Group 1: Financial Performance - In 2024, the company reported a revenue of 5.085 billion yuan and a net profit attributable to shareholders of 13.6075 million yuan [2]. - For Q1 2025, the company achieved a revenue of 1.117 billion yuan, with a net profit of 5.67 million yuan, representing a year-on-year growth of 390.5% [2][4]. - The Q1 2025 financial report indicated a revenue decline of 0.83% compared to the previous year, while the net profit increased by 390.5% [4]. - The company reported a debt ratio of 56.05% and a gross margin of 8.27% [4]. Group 2: Business Segments - The company operates in two main business segments: metal products and chemicals. The metal products segment includes the production and sales of galvanized steel wire, galvanized steel strands, and diamond wire, among others [3]. - The chemical segment primarily focuses on the production and sales of organic silicon and related products [3]. Group 3: Strategic Initiatives - The company is committed to continuous technological upgrades and market management to reduce costs and enhance efficiency [2]. - The company has successfully acquired mining rights for the Longtoushan gold mine and is working on further exploration to verify gold resource reserves [3]. - The company is exploring the tungsten wire market and has developed cold-drawing technology for tungsten wire, indicating a potential shift towards high-margin materials [2].

牧原股份此前曾在业绩预告中表示，公司一季度业绩大增的主要原因是生猪出栏量、生猪销售均价较去年同期上升，且生猪养殖成本较去年同期下降。 其中，营收达到200亿的有3家，营收同比增长的有9家，正邦科技（002157）以108.22%的同比增幅领跑全场；归母净利润超过20亿的有2家，牧原股份 （002714）以44.91亿元稳居榜首；归母净利润实现同比增长的有8家，且除了东瑞股份（001201）增速为93.31%外，其余公司增速均超100%，神农集团 （605296）更是以6510.85%的增速成为当之无愧的"黑马"。 | 证券代码 | 证券简称 | 营业收入 | 营业收入同比变化 | 归母净 | | --- | --- | --- | --- | --- | | | | (亿元) | (%) | | | 002714. SZ | 牧原股份 | 360. 61 | 37. 26 | 44 | | 300498. SZ | 温氏股份 | 243. 18 | 11. 34 | 20 | | 000876. SZ | 新希望 | 244. 17 | 2. 13 | 4. | | 605296. SH | 神农集团 | 1 ...